AGI is a specialty pharmaceutical company which is focused on the development and commercialisation of differentiated drug products for gastrointestinal (GI) diseases and disorders. AGI’s common shares are listed on the Alternative Investment Market of the London Stock Exchange (AIM) and on the Irish Enterprise Exchange of the Irish Stock Market (IEX) as AGI.
The company has a portfolio of product candidates derived from its Known Molecular Entity (KME™) approach to drug re-profiling and development.
Rule 26 Disclosures
Visitors to this website may access those disclosures required by Rule 26 of the AIM and IEX Rules under “Corporate Governance” in the “Investors” section of this website, or by clicking here
